What the DOJ’s shortened FCA review timeline means for healthcare and life sciences organizations

In brief: On May 27, 2026, the Department of Justice (DOJ) issued a memorandum directing its attorneys to fast-track reviews of False Claims Act (FCA) suits alleging fraud against federally funded, state-administered benefits programs. The FCA is the government’s most powerful anti-fraud tool, and most FCA cases begin as “qui tam” actions—suits filed under seal… Continue reading What the DOJ’s shortened FCA review timeline means for healthcare and life sciences organizations